Stocks and Investing
Stocks and Investing
Wed, March 29, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chi Fong Maintained (CCCC) at Hold with Decreased Target to $5 on, Mar 28th, 2023
Chi Fong of B of A Securities, Maintained "C4 Therapeutics, Inc." (CCCC) at Hold with Decreased Target from $11 to $5 on, Mar 28th, 2023.
Chi has made no other calls on CCCC in the last 4 months.
There are 4 other peers that have a rating on CCCC. Out of the 4 peers that are also analyzing CCCC, 1 agrees with Chi's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Derek Archila of "Wells Fargo" Maintained at Hold with Decreased Target to $9 on, Tuesday, January 3rd, 2023
These are the ratings of the 3 analyists that currently disagree with Chi
- Terence Flynn of "Morgan Stanley" Maintained at Sell with Decreased Target to $5 on, Monday, February 27th, 2023
- Eric Joseph of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $5 on, Friday, February 24th, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Friday, February 24th, 2023
Contributing Sources